An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996.

abstract：:Total hip arthroplasty (THA) is a major orthopaedic procedure with a high risk of postoperative thromboembolism. Increasing demand for this type of surgery, together with its high cost, has led to examination of means by which the cost of THA may be minimised. Current clinical opinion favours the use of suitable pharm...

journal_title：PharmacoEconomics

authors： Dunn CJ,Goa KL

更新日期：1996-08-01 00:00:00

abstract：:The efficacy of granisetron in preventing acute nausea and vomiting during the 24 hours following chemotherapy in patients with cancer is equivalent to that of other serotonin 5-HT3 receptor antagonists (ondansetron and tropisetron) and similar to or greater than that of conventional antiemetic regimens such as metocl...

journal_title：PharmacoEconomics

authors： Plosker GL,Benfield P

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:The English community pharmacy New Medicine Service (NMS) significantly increases patient adherence to medicines, compared with normal practice. We examined the cost effectiveness of NMS compared with normal practice by combining adherence improvement and intervention costs with the effect of increased adher...

journal_title：PharmacoEconomics

authors： Elliott RA,Tanajewski L,Gkountouras G,Avery AJ,Barber N,Mehta R,Boyd MJ,Latif A,Chuter A,Waring J

更新日期：2017-12-01 00:00:00

abstract：OBJECTIVE:Economic evaluations of new diabetes therapies rely heavily upon the UK Prospective Diabetes Study (UKPDS) equations for prediction of cardiovascular events; however, concerns persist regarding their relevance to current clinical practice and appropriate use in populations other than newly diagnosed patients....

journal_title：PharmacoEconomics

authors： McEwan P,Bennett H,Ward T,Bergenheim K

更新日期：2015-02-01 00:00:00

abstract：BACKGROUND:Health-related quality of life (HRQoL) is a key outcome in cost-utility analyses, which are commonly used to inform healthcare decisions. Different instruments exist to evaluate HRQoL, however while some jurisdictions have a preferred system, no gold standard exists. Standard meta-analysis struggles with the...

journal_title：PharmacoEconomics

authors： Schmitz S,Makovski TT,Adams R,van den Akker M,Stranges S,Zeegers MP

更新日期：2020-01-01 00:00:00

abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...

journal_title：PharmacoEconomics

authors： Campbell JD,Ramsey SD

更新日期：2009-01-01 00:00:00

abstract：:The past few years have seen rapid changes in the methods of decision-analytic modelling of healthcare programmes for the purposes of economic evaluation. This paper focuses on four developments in modelling that have emerged over the past few years or have become more widely used. First, no one optimal method for ext...

journal_title：PharmacoEconomics

authors： Weinstein MC

更新日期：2006-01-01 00:00:00

abstract：:This study evaluated the cost utility of adding interferon-alpha 2b to conventional treatment in patients with multiple myeloma. It also provides a methodology for transforming complex quality-of-life profiles into a single index value on the conventional 0 to 1 quality-adjusted life-year scale (QALY). From 1990 to 19...

journal_title：PharmacoEconomics

authors： Nord E,Wisløff F,Hjorth M,Westin J

更新日期：1997-07-01 00:00:00

abstract：:Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions ...

journal_title：PharmacoEconomics

authors： Alexandrov AV,Smurawska LT,Bartle W,Oh P

更新日期：1997-05-01 00:00:00

abstract：:Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...

journal_title：PharmacoEconomics

authors： Cramer MP,Saks SR

更新日期：1994-06-01 00:00:00

abstract：:The cost of the development of a new drug product, from concept and synthesis of a new chemical entity to safety and efficacy testing, to the approval process and postmarketing surveillance, has more than quadrupled in the last 20 years. To amortise these costs, the pharmaceutical industry has taken on international ...

journal_title：PharmacoEconomics

authors： Kitler ME

更新日期：1992-11-01 00:00:00

abstract：:Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy in patients with LGS uncontrolled on one to t...

journal_title：PharmacoEconomics

authors： McCormack PL

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China's new Essential Medicines Program (...

journal_title：PharmacoEconomics

authors： Chen M,Wang L,Chen W,Zhang L,Jiang H,Mao W

更新日期：2014-03-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...

journal_title：PharmacoEconomics

authors： Bermejo I,Ren S,Simpson E,Clowes M,Scott DL,Young A,Stevenson M

更新日期：2018-12-01 00:00:00

abstract：BACKGROUND:Several vaccine and antibody candidates are currently in development for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus (RSV). METHODS:We searched MEDLINE, Embase, and SCOPUS and included model-based evaluations of RSV vaccinations. Two reviewers performed the...

journal_title：PharmacoEconomics

authors： Treskova M,Pozo-Martin F,Scholz S,Schönfeld V,Wichmann O,Harder T

更新日期：2021-01-19 00:00:00

abstract：:The symptoms of onychomycosis and their impact on personal appearance are important determinants of patients' perceptions of their own health. The effect of onychomycosis is greater on psychosocial than physical functioning and is directly related to the extent of nail involvement. This review identified a number of d...

journal_title：PharmacoEconomics

authors： Shaw JW,Joish VN,Coons SJ

更新日期：2002-01-01 00:00:00

abstract：:The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE's single technology appraisal process. The Centre for Reviews and Dissemination and the Cent...

journal_title：PharmacoEconomics

authors： Cox E,Wade R,Peron M,Dietz KC,Eastwood A,Palmer S,Griffin S

更新日期：2019-09-01 00:00:00

abstract：:Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

journal_title：PharmacoEconomics

authors： Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

journal_title：PharmacoEconomics

authors： Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Swedish formulary committees are expected to influence prescribing practice by establishing and issuing drug lists and clinical practice guidelines, particularly now that financial responsibility for prescription drugs has been transferred from the national to the county council level. OBJECTIVE:The purpose...

journal_title：PharmacoEconomics

authors： Anell A,Svarvar P

更新日期：2000-02-01 00:00:00

abstract：:Multiple sclerosis (MS) is a disease of the CNS, typically striking adults during the primary productive time of their life. The symptoms of MS can restrict the individual's physical activity and income-earning ability, resulting in a major financial burden on the patient, family, health system and society. This syste...

journal_title：PharmacoEconomics

authors： Naci H,Fleurence R,Birt J,Duhig A

更新日期：2010-01-01 00:00:00

abstract：:Weight Reduction is Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand. ...

journal_title：PharmacoEconomics

authors： Chongmelaxme B,Phisalprapa P,Manthaisong R,Dilokthornsakul P,Chaiyakunapruk N

更新日期：2019-02-01 00:00:00

abstract：:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), sprains and strains, sports injuries and menstrual disorders, and have a small role in the management of patent ductus arteriosus in the neonate. In patients with RA, symptom...

journal_title：PharmacoEconomics

authors： Wynne HA,Campbell M

更新日期：1993-02-01 00:00:00

abstract：:As part of its single technology process, the National Institute for Health and Care Excellence (NICE) invited the manufacturers of aripiprazole (Otsuka Pharmaceutical Co. and Bristol Myers Squibb) to submit evidence of the clinical and cost effectiveness of aripiprazole for the treatment and prevention of acute manic...

journal_title：PharmacoEconomics

authors： Uttley L,Kearns B,Ren S,Stevenson M

更新日期：2013-11-01 00:00:00

abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

journal_title：PharmacoEconomics

authors： Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS:A sys...

journal_title：PharmacoEconomics

authors： Rodriguez-Martinez CE,Sossa-Briceño MP,Castro-Rodriguez JA

更新日期：2018-10-01 00:00:00

abstract：:Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accept...

journal_title：PharmacoEconomics

authors： Iskedjian M,Trakas K,Bradley CA,Addis A,Lanctôt K,Kruk D,Ilersich AL,Einarson TR

更新日期：1997-12-01 00:00:00

abstract：BACKGROUND:The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications. O...

journal_title：PharmacoEconomics

authors： Najafzadeh M,Garces JA,Maciel A

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/ glycosylated haemoglobin A1c (HbA1c) after the failure of metformin mon...

journal_title：PharmacoEconomics

authors： Beale S,Bagust A,Shearer AT,Martin A,Hulme L

更新日期：2006-01-01 00:00:00

abstract：:Randomized controlled trials provide unbiased estimates of treatment effect through reducing the attribution of observed differences in outcome to the play of chance or the treatment of interest. Issues in the design of randomized trials may lead to a dilution or magnification of treatment effect when compared with cl...

journal_title：PharmacoEconomics

authors： Freemantle N,Hessel F

更新日期：2009-01-01 00:00:00